IL31RA and Alzheimer disease: CCL27 in the stratum corneum has been proposed as a biomarker of clinical response to nemolizumab, an anti-IL-31RA, treatment in AD (42), supporting the significant correlation between CCL27 and SCORAD in group 1 of patients.